TELA Bio Inc (TELA)

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership

After Fifty Years of Implants, a Newly Public Biotech Is Trying to Rebuild the Breast Instead

Conexeu Sciences just 3D-bioprinted a new tissue matrix to one of the most respected regenerative medicine...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues

MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical...

TELA Bio to Announce First Quarter 2026 Financial Results

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a...

Form S-8 - Securities to be offered to employees in employee benefit plans